ReviewCureus2026
Adiponectin Signaling Dysfunction and Pro-inflammation in Perivascular Adipose Tissue in Non-obstructive Ischemic Heart Disease: A Narrative Literature Review of New Endocrine-Metabolic Therapeutic Targets.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia with non-obstructive coronary arteries (INOCA)/myocardial infarction with non-obstructive coronary arteries (MINOCA) affects a substantial proportion of patients undergoing coronary angiography; however, its pathophysiology remains incompletely understood, and evidence-based management remains limited. This narrative review synthesizes mechanistic, translational, and clinical evidence linking pericoronary perivascular adipose tissue (PVAT) dysfunction to coronary microvascular dysfunction (CMD) and vasomotor dysregulation in the absence of epicardial stenosis. A comprehensive literature search was conducted across PubMed/MEDLINE, Scopus, the Cochrane Library, and Google Scholar up to March 2025, encompassing preclinical studies, observational cohorts, imaging studies, and clinical trials across five thematic domains: PVAT physiology, adiponectin signaling, PVAT phenotypic transition in INOCA/MINOCA, pericoronary fat attenuation index (FAI), and endocrine-metabolic therapeutic targets. In healthy individuals, PVAT maintains coronary homeostasis through adiponectin-mediated AMP-activated protein kinase (AMPK)-endothelial nitric oxide synthase (eNOS)-nitric oxide signaling and anti-inflammatory paracrine effects. Under metabolic dysfunction, PVAT undergoes a phenotypic transition characterized by reduced adiponectin secretion and increased production of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and reactive oxygen species, thereby impairing endothelium-dependent vasodilation and promoting microvascular dysfunction. In MINOCA, distinct mechanisms including Rho-kinase activation and TNF-α-driven α1-adrenergic upregulation drive vasospasm. Pericoronary FAI has demonstrated independent prognostic value across obstructive and non-obstructive coronary disease. Therapeutic strategies including sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists show mechanistic promise for PVAT remodeling, though dedicated randomized evidence in non-diabetic INOCA populations remains limited. These findings support repositioning PVAT as a therapeutic target in non-obstructive ischemic disease, pending prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.